Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Earnings Results, Misses Expectations By $0.14 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) released its earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14), FiscalAI reports. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.23 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• Both Phase III wet AMD trials missed their primary endpoint in the full analysis population. EyePoint highlighted DURAVYU’s biological activity, reduced treatment burden, and safety, but is discontinuing the wet AMD program while it reviews whether any patient subgroup could support a future path.
• EyePoint ended September with about $118 million in cash and expects to fund operations into late Q3 2027, while COMO and CAPRI results are expected in early Q4 2027. Management says it is evaluating additional cost reductions, financing, and business-development options to preserve runway and reach the readouts.
• EyePoint is concentrating its clinical efforts on DME, citing the disease’s distinct biology and Phase II VERONA results, including vision improvement and fewer supplemental injections with DURAVYU. The company expects simultaneous top-line results from the two Phase III trials, which enrolled more than 550 patients, in early Q4 2027; efficacy in these pivotal studies remains unproven.
• After the wet AMD results, EyePoint amended DME rescue-injection criteria so patients may receive supplemental treatment after a greater-than-five-letter BCVA decline from baseline alongside a CST increase of at least 50 microns. The company says the change is intended to help preserve vision and protect the trials’ non-inferiority objective; it is not planning a futility analysis.
• EyePoint plans to reduce its workforce by about 53% and says the move will generate approximately $30 million in annualized savings once fully implemented, aligning spending with the DME program.

Eyepoint Pharmaceuticals Stock Down 10.4%

NASDAQ:EYPT opened at $0.32 on Friday. The firm has a market capitalization of $27.54 million, a P/E ratio of -0.09 and a beta of 1.84. The company has a fifty day moving average of $2.41 and a 200 day moving average of $10.32. Eyepoint Pharmaceuticals has a 52 week low of $0.31 and a 52 week high of $19.11.

Wall Street Analyst Weigh In

Several research firms have commented on EYPT. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. Guggenheim lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, October 19th. Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, September 27th. Finally, Laidlaw cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 20th. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.